Genprex Inc

GNPX

Company Profile

  • Business description

    Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

  • Contact

    3300 Bee Cave Road
    Suite 650-227
    AustinTX78746
    USA

    T: +1 877 774-4679

    https://www.genprex.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    13

Stocks News & Analysis

stocks

Weekly Earnings Wrap: CBA, CSL, MQG and more

Everything you need to know on last weeks earnings results
stocks

ASX player rallies on small guidance upgrade

Our fair value is maintained despite investor enthusiasm.
stocks

After earnings, is Alphabet stock a buy, a sell, or fairly valued?

With strong fourth-quarter earnings and AI integration, here’s what we think of Alphabet stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,138.8045.70-0.50%
CAC 408,311.7428.82-0.35%
DAX 4024,914.8862.190.25%
Dow JONES (US)49,500.9348.950.10%
FTSE 10010,446.3543.910.42%
HKSE26,567.12616.03-2.27%
NASDAQ22,546.6750.48-0.22%
Nikkei 22556,941.97708.57-1.23%
NZX 50 Index13,198.18248.19-1.85%
S&P 5006,836.173.410.05%
S&P/ASX 2008,917.601.600.02%
SSE Composite Index4,082.0751.95-1.26%

Market Movers